Bristol Myers goes all-in on Nvidia
The day's biggest story is a hardware bet. Bristol Myers Squibb is buying Nvidia's latest-generation AI computing system to power artificial intelligence across its drug research, deepening an existing partnership with the chipmaker. The New Jersey–headquartered drugmaker, which announced the move Monday and was reported by Reuters, is billing the result as the most powerful AI system in the pharmaceutical industry.
BMS isn't alone. A growing list of drugmakers is wiring up Nvidia silicon to speed how new medicines are discovered and developed. Per simplywall.st, Certara has entered its own AI partnership with Nvidia — a sign that access to cutting-edge compute is fast becoming table stakes for serious drug discovery, not a differentiator reserved for the largest players.
Deals and dollars
The money kept moving elsewhere too. Tempus AI agreed to acquire cancer-test maker Personalis in a deal valued at $1.5 billion, according to BioPharma Dive. Both companies work in cancer diagnostics — the tests that help detect disease — so the tie-up consolidates two players in the same fast-growing corner of oncology.
On the fundraising side, several stories point the same direction: capital is flowing back into biotech. Latigo Pharmaceuticals, a Westlake-founded biotech developing non-opioid pain treatments that target sodium ion channels, laid out plans to go public, BioPharma Dive reports — an IPO meant to fund its pipeline. Zoom out and the trend is striking: Endpoints News reports that British biotech companies pulled in more venture capital in the second quarter of 2026 than in any full year since 2022, a record that suggests the UK sector's funding drought has decisively broken. And in medical AI specifically, OpenEvidence — which builds AI tools for medicine — is weighing a roughly $200 million raise, according to PYMNTS.com via Google News.
AI reaches deeper into the clinic
Beyond the deals, researchers are pushing AI into diagnosis and care. A study covered by South Korea's Maeil Business Newspaper suggests AI can forecast how a patient will fare, including their risk of dying — the kind of prognostic tool that could reshape triage if it holds up. Others are getting more specialized: researchers have built an AI agent aimed squarely at atrial fibrillation, one of the most common heart conditions, an irregular and often rapid rhythm that can raise the risk of stroke.
The science is also getting more exotic. A new approach reported by Science 2.0 uses quantum sampling to explore "peptide space" — the enormous universe of possible short, protein-like molecules made from chains of amino acids. It's an early hint at how emerging computing paradigms might complement the AI-and-GPU boom in the search for new drugs.
A note of caution from China
Amid the enthusiasm, one voice urged restraint. China's medical technology sector is racing to weave AI into hospital equipment, but United Imaging's AI arm is deliberately pumping the brakes. Its co-CEO told Reuters the company is rejecting an "extreme" rollout — a reminder that as pharma and medtech pour money into powerful new systems, the pace of deployment is itself becoming a strategic choice.
The throughline for the day is clear: from Nvidia supercomputers to billion-dollar diagnostics deals to a record quarter for UK biotech, AI and the capital chasing it are now central to how medicine gets made.